Today: 21 May 2026
Browse Category

ASX:SUN 13 December 2025 - 24 April 2026

ASX 200 Falls Again as Oil Shock Splits Australia Stock Market Before RBA Test

ASX 200 Falls Again as Oil Shock Splits Australia Stock Market Before RBA Test

Australian shares fell for a fourth straight session Friday, with the S&P/ASX 200 down 0.1% to 8,786.5. Suncorp rose 4.9% after announcing new reinsurance cover, while IGO plunged 17.3% on lower production guidance for Greenbushes spodumene. Brent crude traded above $105 a barrel amid Strait of Hormuz tensions. Investors favored energy and utilities as basic materials and real estate lagged.
24 April 2026
·····
Suncorp Group Limited (ASX: SUN) Stock Outlook: Storm-Claims Update, Reinsurance Impact, Buyback Support and Analyst Targets for the Week Ahead (Updated 14 Dec 2025)

Suncorp Group Limited (ASX: SUN) Stock Outlook: Storm-Claims Update, Reinsurance Impact, Buyback Support and Analyst Targets for the Week Ahead (Updated 14 Dec 2025)

Suncorp Group (ASX: SUN) reported over 18,000 insurance claims after late-November storms, calling it one of Queensland’s largest hail events. The company expects a net storm cost of A$350 million, reaching its reinsurance retention limit. SUN shares traded near A$17.30 this week, close to the lower end of their 52-week range.
14 December 2025
·
Suncorp Group Limited (ASX: SUN) Stock: Latest Storm-Cost Update, Share Buyback Signals and Analyst Forecasts as of 13 December 2025

Suncorp Group Limited (ASX: SUN) Stock: Latest Storm-Cost Update, Share Buyback Signals and Analyst Forecasts as of 13 December 2025

Suncorp shares closed at A$17.30 on Friday, 12 December 2025, about 4% above the 52-week low set earlier in the month. The company reported over 10,000 storm-related claims and estimated net costs at A$350 million, reaching its reinsurance maximum event retention. Total natural hazard costs for the period hit up to A$1.275 billion, still within its FY26 allowance of A$1.77 billion.
13 December 2025
··

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop